invasive fungal infection
Conditions
Interventions
Case series:oral posaconazole 5ml, tid
Sponsors
hematology department of The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
13 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult patients over 13 years of age with posaconazole for blood disease or hematopoietic stem cell transplantation. Blood diseases include aplastic anemia, acute myeloid leukemia, acute lymphocytic leukemia, non-hodgkin's lymphoma, multiple myeloma, or other blood tumor diseases; 2. Patients were expected to have or have documented persistent neutropenia (absolute neutropenia count (ANC) <= 0.5*10^9/L) and sustained for at least 7 days; 3. The patient or his authorized client agrees to participate in the clinical trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients allergic to posaconazole; 2. Patients without informed consent; 3. Any predictable increase in patient risk or other factors that can interfere with clinical trial results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| breakthrough infection after drug using; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Events;plasma concentration;absolute neutrophil count;duration of Agranulocytosis; | — |
Countries
China
Contacts
Public ContactAining Sun
The First Affiliated Hospital of Soochow University
Outcome results
None listed